Mabwell Receives NMPA Approval for Clinical Trial of 9MW3011 in Rare Diseases
China – based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has...
Staidson’s Anti-C5a Monoclonal Antibody STSA-1002 Accepted for NMPA Review
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced that the clinical trial filing...
Guangdong Raynovent Biotech Secures RMB 370 Million in Series C Financing
Guangdong Raynovent Biotech Co., Ltd, a controlling subsidiary of China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd...
Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the appointment of Dr. “Frank” Jiang Ningjun...
Junshi Biosciences’ CGRP Monoclonal Antibody JS010 Accepted for NMPA Review
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that the clinical trial filing for...
BeiGene’s Tislelizumab Receives NMPA Review for First-Line HCC Indication
BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has revealed that a supplementary Biologic License Application...
Immunohead Biotech Raises RMB 200 Million in Series A+ Financing Round
Immunohead Biotechnology Co., Ltd, a cell therapy developer based in Suzhou, has reportedly raised close...
Biocytogen and Hansoh Enter Antibody Collaboration and Licensing Agreement
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an antibody collaboration, assignment, and exclusive license...
CStone Pharmaceuticals Achieves Primary Endpoint in GEMSTONE-304 Study for Sugemalimab
China-based CStone Pharmaceuticals (HKG: 2616) has announced the achievement of the primary endpoint in the...
3D Medicines Gains FDA Approval for Phase II Study of Envafolimab in dMMR Tumors
China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving approval from the US FDA...
Changzhou Qianhong Completes Phase I Study of QHRD107 for Acute Myeloid Leukemia
China-based Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550) has announced the completion of enrollment and...
Guangdong Zhongsheng Completes Enrollment for RAY1216 Phase III Study in COVID-19
China – based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the completion of...
CDE Releases 65th Batch of Chemical Generic Reference Preparations
The Center for Drug Evaluation (CDE) has released the 65th batch of chemical generic reference...
Viking Therapeutics Sues Ascletis Pharma Over Alleged Trade Secret Theft
US – based Viking Therapeutics (NASDAQ: VKTX) is set to take China’s Ascletis Pharma Inc....
Shuwen Biotech Partners with Nottingham University Hospitals for MammaTyper
China – based diagnostic specialist Shuwen Biotech Co., Ltd and its German wholly – owned...
Chinagene Tech’s ZVS101e Receives FDA IND Approval for Bietti’s Crystalline Dystrophy
Beijing – based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has...
Jiangxi Leads 16-Province VBP Alliance with Winning Bids Announced
The Jiangxi Province Healthcare Security Administration has released a notification regarding the winning bids of...
NMPA Approves 172 Medical Devices for Marketing in November 2022
The National Medical Products Administration (NMPA) approved 172 medical devices for marketing in November 2022....
Merck’s Lagevrio Receives Emergency Conditional Approval from China’s NMPA
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced receiving emergency conditional approval...
NHSA and CNIPA Issue Opinions on Strengthening IP Protection in Drug Procurement
The National Healthcare Security Administration (NHSA) and the China National Intellectual Property Administration (CNIPA) have...